10-K: SI-BONE Reports Revenue Growth Amidst Persistent Losses

SI-BONE, Inc. reported a 20.2% revenue increase to $200.9 million in 2025, driven by expanded product offerings and physician base, despite incurring a net loss of $18.9 million.

Summary

• Revenue increased by 20.2% to $200.9 million for the year ended December 31, 2025, up from $167.2 million in 2024.
• Net loss for 2025 was $18.9 million, an improvement from $30.9 million in 2024 and $43.3 million in 2023.
• Gross profit rose to $159.9 million in 2025 from $132.1 million in 2024, with gross margin improving slightly to 79.6% from 79.0%.
• Operating expenses increased by 8.9% to $182.2 million in 2025, primarily due to higher sales and marketing costs ($124.2 million) and general and administrative expenses ($40.5 million).
• Research and development expenses increased by 5.4% to $17.4 million in 2025, reflecting continued investment in new products.
• Cash and marketable securities stood at $147.8 million as of December 31, 2025, a slight decrease from $150.0 million in 2024.
• The company had $35.6 million in outstanding debt as of December 31, 2025, related to a term loan with First-Citizens Bank & Trust Company.
• Over 140,000 procedures have been performed using SI-BONE products since iFuse was introduced in 2009.
• The total addressable market in the United States is estimated to exceed $3.5 billion, including sacroiliac joint dysfunction ($2.4 billion), thoracolumbar fixation and fusion ($1.0 billion), and pelvic trauma ($350 million).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing. Strong revenue growth and improving net loss are encouraging, supported by product innovation and favorable reimbursement for key devices. However, persistent losses, reliance on single suppliers, and an ongoing DOJ investigation introduce notable risks that temper a higher sentiment score.

Positives

• Revenue grew by 20.2% year-over-year, indicating strong market acceptance and commercial execution.
• Net loss decreased significantly from $30.9 million in 2024 to $18.9 million in 2025, showing progress towards profitability.
• Gross margin improved to 79.6% in 2025, reflecting favorable product mix and operational efficiencies.
• Three platform technologies (iFuse Bedrock Granite, iFuse TORQ TNT) have received FDA Breakthrough Device Designation, highlighting innovation.
• iFuse TORQ TNT received a New Technology Add-on Payment (NTAP) from CMS, providing incremental reimbursement of up to $4,136 per eligible inpatient procedure until September 30, 2028.
• iFuse Bedrock Granite is eligible for Transitional Pass-Through (TPT) payment in outpatient settings effective January 1, 2025, which passes through total facility-reported costs to Medicare.
• The company maintains a strong clinical evidence base with over 180 publications, including four prospective randomized controlled trials, supporting the safety, effectiveness, durability, and economic utility of its iFuse implants.
• Expansion of the U.S. sales force to 89 territory sales managers and 83 clinical support specialists, and 320 third-party sales agents as of December 31, 2025, supports continued growth.
• Average revenue per territory sales manager increased to approximately $2.1 million in fiscal year 2025 from $1.8 million in 2024, indicating improved productivity.

Negatives

• The company continues to incur significant operating losses, with an accumulated deficit of $450.3 million as of December 31, 2025.
• Reliance on a limited number of third-party suppliers, some single-source, for most products and components poses supply chain risks.
• Uncertainty in coverage and reimbursement for newer products (e.g., CPT Code 27278 for iFuse INTRA X) may decrease demand.
• Increased competition and healthcare provider consolidation may lead to pricing pressure and reduced profit margins.
• The shift of procedures to ambulatory surgical centers (ASCs) and office-based labs (OBLs) generally results in more acute pricing pressure on products.
• High dependence on revenue from a single product family (sacroiliac joint stabilization and fusion) makes the company vulnerable to market shifts or competitive threats in that segment.
• Interest income decreased by 22.6% in 2025 due to lower interest rates on marketable securities.

Risks

• Intense competition from major medical device companies with greater resources and broader product offerings, potentially leading to product obsolescence or pricing pressure.
• Inability to achieve or sustain future profitability due to continued operating losses and increasing operating expenses.
• Inadequate or uncertain coverage and reimbursement from third-party payors for procedures using products, particularly for newer products or in certain settings (e.g., CPT Code 27278).
• Dependence on a limited number of third-party suppliers, including single-source suppliers like RMS Company, for critical components and manufacturing, risking supply disruptions and increased costs.
• Prolonged inflation and supply chain disruptions could result in delayed product launches, lost revenue, higher costs, and decreased profit margins.
• Physicians and payors may not find clinical evidence for more recent products compelling, limiting sales and revenue, and future research could show products are less safe or effective.
• Inability to maintain and expand the network of direct sales representatives, third-party sales agents, and resellers, impacting sales generation.
• Loss of key members of senior management, key advisors, or personnel could adversely affect business operations.
• Adverse events related to products could lead to market withdrawal, safety warnings, sales limitations, or product liability claims.
• Failure to comply with extensive governmental regulations in the U.S. and abroad (FDA, EU MDR, fraud and abuse laws) could result in enforcement actions, fines, or market restrictions.
• Cybersecurity threats, including data breaches and ransomware attacks, could compromise IT systems and sensitive data, leading to regulatory actions, litigation, and reputational harm.
• Implementation of artificial intelligence and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences.
• Inability to adequately protect or enforce intellectual property rights or secure rights to patents of others, diminishing the value of intellectual property and impairing commercialization.
• Potential product liability losses, with insurance coverage possibly being inadequate or unavailable.
• Risks associated with non-U.S. operations, including differing legal standards, lack of intellectual property protection, and political/economic instability.
• Unfavorable media reports or negative publicity concerning tissue recovery or disease transmission could limit acceptance of human tissue-derived products (iFuse INTRA/INTRA X).
• Adverse developments affecting the banking industry or broader financial services industry could impact operations and liquidity.
• Loan and security agreement contains covenants that may restrict business and financing activities.

Future Outlook

The company expects operating expenses to continue increasing due to ongoing development, enhancement, and commercialization of existing and new products, and growth of its commercial infrastructure. It anticipates continued investments in research and development. The company believes its existing cash and marketable securities will fund operating expenses and capital expenditure requirements for the next 12 months and beyond, but acknowledges potential challenges from economic downturns or capital market disruptions, and the need for additional capital for new product offerings.

Management Comments

• We are a leader in developing innovative procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific innovation.
• Our focus on innovation has resulted in three of our platform technologies being designated as breakthrough devices by the FDA.
• We continue to focus on the development of products and techniques to help physicians improve the treatment of their patients with compromised bone.
• Robust clinical evidence is central to drive adoption and favorable reimbursement, and we remain focused on continuing to set the industry standard in delivering evidence-based care.
• We continue to actively engage with ASCs to educate their management groups on our clinical evidence, exclusive commercial payor coverage and focus on driving improved education and pathways between pain physicians and surgeons.
• Our ability to recruit, develop and retain highly skilled talent is a significant determinant of our success.
• We are focused on increasing our territory sales managers and sales representatives capacity, efficiency and productivity.
• We are working closely with our suppliers to reduce lead time for our implants to ensure we can support our expanding physician footprint and over time build the resilience in our supply chain to reduce our cash investment in inventory.
• We are partnering with our suppliers around design for manufacturing, specifically for newer products, to reduce the overall cost of the implants as we scale, and reduce waste and rework.

Industry Context

StockSavvy.ai notes that SI-BONE operates in the highly competitive medical device industry, particularly within spinal and pelvic health. The company's emphasis on minimally invasive solutions and strong clinical evidence aligns with broader industry trends favoring less invasive procedures and value-based care. Its receipt of FDA Breakthrough Device Designations and specific reimbursement codes (NTAP, TPT) for certain products positions it favorably against competitors like Alphatec Holding Inc., Globus Medical, Inc., and Medtronic plc., who often leverage broader product portfolios and integrated surgical platforms. The industry is also experiencing a shift towards ambulatory surgical centers (ASCs) and office-based labs (OBLs) for cost control, which presents both opportunities and pricing pressures for device manufacturers.

Comparison to Industry Standards

• SI-BONE's gross margin of 79.6% in 2025 is strong, indicating efficient production or premium pricing, and compares favorably to many medical device companies, which often range from 60-80%.
• The company's continued net losses, despite revenue growth, suggest it is still in a growth phase requiring significant investment, similar to many emerging medical technology companies, but contrasts with more established, profitable industry leaders like Medtronic plc. or Globus Medical, Inc.
• The reliance on a direct sales force and third-party agents is a common model in the medical device sector, with SI-BONE's expansion of its U.S. sales force to 172 direct employees and 320 third-party agents reflecting a commitment to market penetration comparable to specialized segments of larger competitors.
• The company's investment in clinical evidence, including four prospective randomized controlled trials, sets a high standard for product validation, often exceeding the evidence base for less differentiated screw systems offered by smaller competitors in the sacroiliac fusion market.
• The FDA Breakthrough Device Designations for iFuse Bedrock Granite and iFuse TORQ TNT indicate a level of innovation recognized by regulators, potentially offering a competitive edge similar to other companies developing novel therapies in unmet medical needs.

Management Changes

Corporate Governance

Legal Proceedings

• Received a civil investigative demand (CID) from the U.S. Department of Justice, Civil Division, in October 2024, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.
• The CID requests information and documents primarily relating to meals and consulting service payments provided to healthcare professionals.
• The company is cooperating with the investigation but is unable to predict its duration, outcome, or potential financial impact, which could be material.
• The company is subject to various potential loss contingencies arising in the ordinary course of business, with outcomes not within its control and potentially unknown for prolonged periods.

Related Party Transactions

• Entered into consulting agreements and royalty agreements with physicians and healthcare executives, including some who are customers.
• Engages in co-marketing arrangements with certain physicians who use products.
• Prior to IPO, a small number of current customer surgeons acquired less than 1.0% of current outstanding common stock, either purchased in arms-length transactions or received as fair market value for consulting services.

Stakeholder Impact

• **Shareholders**: Potential for increased value from revenue growth and reduced net losses, but exposed to risks from ongoing legal investigation, competitive pressures, and the need for future capital raises.
• **Employees**: Continued investment in human capital resources, including competitive compensation, benefits, and professional development, aims to attract and retain skilled talent. However, potential for workforce reductions or program cuts due to government policies could impact employees.
• **Customers (Hospitals, Physicians, ASCs, OBLs)**: Benefit from innovative product solutions and training programs. Impacted by evolving reimbursement policies and pricing pressures, which could influence product adoption.
• **Suppliers**: Continued reliance on a limited number of third-party suppliers, including single-source providers, creates interdependence. Supply chain disruptions or changes in manufacturing agreements could affect both parties.
• **Patients**: Benefit from new and improved minimally invasive treatment options for sacroiliac joint dysfunction, thoracolumbar fixation, and pelvic trauma, supported by clinical evidence and breakthrough device designations.

Next Steps

• Continue to develop, enhance, and commercialize existing and new products.
• Expand the sales force and commercial infrastructure to drive adoption and revenue growth.
• Invest in research and development initiatives to bring new and differentiated solutions to market.
• Monitor and respond to employee sentiment to enhance retention and job satisfaction.
• Optimize business processes to identify, measure, and improve operational efficiency, including supply chain resilience and asset utilization.
• Cooperate with the U.S. Department of Justice in its civil investigative demand related to the Anti-Kickback Statute and Civil False Claims Act.
• CMS review of MS-DRG reassignment for iFuse Bedrock Granite for FY 2027 rule making cycle.
• Continue to evaluate the impact of new accounting standards (ASU 2025-12, ASU 2025-11, ASU 2025-06, ASU 2024-03) on disclosures and accounting practices.
• Relocate corporate headquarters, research and development, and warehouse space to San Jose, California, with the new lease commencing in October 2026.

Key Dates

Recommendation

The company demonstrates strong revenue growth and improving net loss, driven by product innovation and strategic market expansion. Favorable reimbursement designations for key products are positive. However, the persistent operating losses, significant dependence on a single product family, reliance on limited suppliers, and the ongoing U.S. Department of Justice investigation introduce substantial uncertainties and risks. A 'hold' recommendation is appropriate as the positive momentum is balanced by these material risks, suggesting investors should await further clarity on profitability and the legal proceedings before making a more definitive investment decision.

Keywords

Sacroiliac Joint Fusion, Minimally Invasive Surgery, Medical Devices, Spinal Fusion, Pelvic Trauma, Orthopedic Surgery, FDA Clearance, Reimbursement, 3D Printing, iFuse, Healthcare Technology, Biomechanical Design